Management options for Takayasu arteritis. (September 2013)

• Record Type: Journal Article
• Authors: Tombetti, Enrico; Manfredi, Angelo; Sabbadini, Maria Grazia; Baldissera, Elena
• Is Part Of: Expert opinion on orphan drugs. Volume 1:Number 9(2013:Sep.)
• Page Start: 685
• Page End: 693
• Publication Date: 2013-09
• Subjects: angioplasty -- medical therapy -- surgery -- Takayasu arteritis -- TNF inhibitors; Orphan drugs -- Periodicals; Rare diseases -- Periodicals; Chemotherapy -- Periodicals; 615.1
• DOI: 10.1517/21678707.2013.827570
• Languages: English
• ISSNs: 2167-8707

Abstract

Abstract : Introduction: Takayasu arteritis (TA) is a rare, large vessel vasculitis, which is characterized by substantial morbidity and premature mortality. Several approaches have been used in the recent years for the management of the disease, with some promising results. The best therapeutic strategies still need to be identified. Areas covered: This article discusses the main clinical features of TA and the recent insights into diagnosis and treatments. A search has been undertaken on PubMed and Scopus databases and the most relevant references have been considered. Expert opinion: The identification of the most effective regimens able to control TA unrelenting vascular inflammation without undue toxicity remains a challenge. To define the validated biomarkers and the activity criteria reflecting the specific features of vascular inflammation, and possibly predicting its outcome, represents a critical challenge for physicians in the next years.